Indantadol Hydrochloride(Indantadol Hydrochloride) - 药物靶点：MAO-A x MAO-B x NMDA receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Indantadol

+ [14]

靶点

MAO-A x MAO-B x NMDA receptor

作用机制

MAO-A抑制剂(单胺氧化酶A抑制剂)、MAO-B抑制剂(单胺氧化酶B抑制剂)、NMDA receptor拮抗剂(谷氨酸[NMDA]受体复合体拮抗剂)

治疗领域

神经系统疾病内分泌与代谢疾病呼吸系统疾病

在研适应症-

非在研适应症

咳嗽糖尿病周围神经性疼痛神经痛+ [2]

原研机构

CHIESI Farmaceutici SpA

在研机构-

非在研机构

Vernalis (R&D) Ltd.Cita NeuroPharmaceuticals, Inc.

Ligand UK Ltd.

+ [1]

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C11H14N2O

InChIKeyMNLULKBKWKTZPE-UHFFFAOYSA-N

CAS号202844-10-8

查看全部结构式(2)

关联

5

项与 Indantadol Hydrochloride 相关的临床试验

NCT01401673 / Terminated临床2期

Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients Attending a Specialist Clinic

The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. Central sensitisation is a hyper-excitability of the sensory nerves as they join the central nervous system, and is believed to be mediated by the N-Methyl-D-Aspartate (NMDA) receptor[1-3].

开始日期2009-10-01

申办/合作机构

Vernalis (R&D) Ltd.

[+1]

EUCTR2009-011525-13-GB / Not yet recruitingN/A

Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients attending a Specialist Clinic - Phase II Open-Label Pilot Study of V3381 in Chronic Cough

开始日期2009-08-28

申办/合作机构

Vernalis (R&D) Ltd.

EUCTR2008-007978-38-GB / Not yet recruitingN/A

A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for Up to 13 Weeks in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) - IN-STEP (Indantadol - Safety Tolerability and Efficacy in Pain)

开始日期2009-02-12

申办/合作机构-

100 项与 Indantadol Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Indantadol Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Indantadol Hydrochloride 相关的专利（医药）

登录后查看更多信息

813

项与 Indantadol Hydrochloride 相关的文献（医药）

2023-02-23·Blood

Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling

Article

作者: Kovtonyuk, Larisa V. ; Gonullu, Nagihan G. ; Manz, Markus G. ; Fullin, Jonas ; Caiado, Francisco ; Boettcher, Steffen

AbstractClonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis, is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells in ≥4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease, and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating cell-extrinsic drivers, like inflammation, remains underexplored. Using bone marrow (BM) transplantation and newly developed genetic mosaicism (HSC-SCL-Cre-ERT; Tet2+/flox; R26+/tm6[CAG-ZsGreen1]Hze) mouse models of Tet2+/−driven CHIP, we observed an association between increased Tet2+/− clonal expansion and higher BM levels of the inflammatory cytokine interleukin-1 (IL-1) upon aging. Administration of IL-1 to mice carrying CHIP led to an IL-1 receptor 1 (IL-1R1)–dependent expansion of Tet2+/− hematopoietic stem and progenitor cells (HSPCs) and mature blood cells. This expansion was caused by increased Tet2+/− HSPC cell cycle progression, increased multilineage differentiation, and higher repopulation capacity compared with their wild-type counterparts. In agreement, IL-1α–treated Tet2+/− hematopoietic stem cells showed increased DNA replication and repair transcriptomic signatures and reduced susceptibility to IL-1α–mediated downregulation of self-renewal genes. More important, genetic deletion of IL-1R1 in Tet2+/− HPSCs or pharmacologic inhibition of IL-1 signaling impaired Tet2+/− clonal expansion, establishing the IL-1 pathway as a relevant and therapeutically targetable driver of Tet2+/− CHIP progression during aging.

2022-09-01·Annals of the Rheumatic Diseases

Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli

Article

作者: Ciceri, Fabio ; Dagna, Lorenzo ; De Luca, Giacomo ; Della-Torre, Emanuel ; Campochiaro, Corrado ; Cavalli, Giulio ; Zangrillo, Alberto

A polemic in response to Ferraccioli et al is given.This article describes the open-label trials with sarilumab, tocilizumab, anakinra and mavrilimumab in patients with severe hyperinflamed COVID-19.In this article the IL-1 or GM-CSF seems a more promising approach since upstream blockade of the inflammatory cascade may allow a better control of cytokine storm-induced organ damage with a better safety profile are discussed.

2022-02-01·Nature Reviews Rheumatology1区 · 医学

DRESS linked to HLA alleles

1区 · 医学

Article

作者: Onuora, Sarah

A review.A case-control study suggest that delayed hypersensitivity reactions to IL-1 or IL-6 inhibitors are strongly associated with a common HLA class II haplotype.The researchers suggest that HLA testing should be considered as part of pre-prescription risk assessment, and that vigilance for DRESS is needed during treatment with IL-1 and IL-6 inhibitors.

100 项与 Indantadol Hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Indantadol Hydrochloride	-	DB12664

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
咳嗽	临床2期	英国	Ligand UK Ltd.	2009-10-01
难治性慢性咳嗽	临床2期	英国	Vernalis (R&D) Ltd.	2009-06-18
不明原因的慢性咳嗽	临床2期	英国	Vernalis (R&D) Ltd.	2009-06-18
糖尿病周围神经性疼痛	临床2期	加拿大	Cita NeuroPharmaceuticals, Inc.	2006-06-01
糖尿病周围神经性疼痛	临床2期	美国	Vernalis (R&D) Ltd.	2006-06-01
糖尿病周围神经性疼痛	临床2期	美国	Cita NeuroPharmaceuticals, Inc.	2006-06-01
糖尿病周围神经性疼痛	临床2期	加拿大	Vernalis (R&D) Ltd.	2006-06-01
神经痛	临床2期	-	CHIESI Farmaceutici SpA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2003	N/A	-	-	IL-1	鑰範鬱鹹鏇願顧遞簾膚(顧鹽範憲遞鹽製繭構餘) = 構顧憲窪醖鹹鹹膚願鑰餘淵襯製獵壓憲獵糧廠 (觸淵遞繭衊艱淵醖觸遞 ) 更多	-	2003-05-01